持续神经肌肉阻滞患者早期肠内营养:基于全国住院数据库的倾向性匹配分析
该回顾性行政数据库研究纳入2010年7月至2016年3月日本超过1200家急性期医院中机械通气且接受持续神经肌肉阻滞剂治疗(罗库溴铵≥250 mg/d或维库溴铵≥50 mg/d连续至少2天)的2340例ICU患者,其中378例(16%)接受了早期肠内营养(神经肌肉阻滞剂启动后2天内)。经1:3倾向性评分匹配形成374对1122对,早期肠内营养组住院死亡率显著更低(风险差-6.3%,95%CI -11.7%至-0.9%),两组医院获得性肺炎发生率无显著差异(风险差2.8%,95%CI -2.7%至8.3%),幸存者住院时间显著更短(风险差-11.4天,95%CI -19.1至-3.7天),ICU停留时间和机械通气时间无显著差异。作者认为早期肠内营养可能与住院死亡率更低相关且不增加医院获得性肺炎。
要点
- 在机械通气且持续使用神经肌肉阻滞剂(罗库溴铵≥250 mg/d或维库溴铵≥50 mg/d连续至少2天)的ICU患者中,2天内启动肠内营养与住院死亡率更低相关(风险差-6.3%,95%CI -11.7%至-0.9%)。
- 早期肠内营养组与晚期肠内营养组的医院获得性肺炎发生率无显著差异(风险差2.8%,95%CI -2.7%至8.3%)。
- 幸存者中早期肠内营养组住院时间显著更短(风险差-11.4天,95%CI -19.1至-3.7天)。
- 两组幸存者的ICU停留时间和机械通气时间无显著差异。
- 该研究为回顾性行政数据库研究,早期肠内营养与结局的关联可能受未测量混杂影响,作者结论为「可能相关」。
适用人群与场景
- 日本超过1200家急性期医院(覆盖约90% tertiary-care emergency hospitals)ICU中机械通气的成人患者。
- 纳入标准:接受持续神经肌肉阻滞剂治疗,定义为罗库溴铵≥250 mg/d或维库溴铵≥50 mg/d连续至少2天。
诊断标准与关键阈值
- 持续神经肌肉阻滞剂治疗定义:罗库溴铵≥250 mg/d或维库溴铵≥50 mg/d,连续至少2天。
- 早期肠内营养定义:神经肌肉阻滞剂启动后2天内开始肠内营养。
研究设计与关键结果
- 研究类型:回顾性行政数据库研究,时间范围2010年7月至2016年3月(69个月),数据来自日本超过1200家急性期医院。
- 样本量:共识别2340例符合条件患者,其中378例(16%)接受早期肠内营养。
- 倾向性评分匹配:1:3匹配,形成374对1122对。
- 主要终点:住院死亡率早期肠内营养组显著低于晚期肠内营养组(风险差-6.3%,95%CI -11.7%至-0.9%)。
- 关键次要终点:医院获得性肺炎发生率两组无显著差异(风险差2.8%,95%CI -2.7%至8.3%);幸存者住院时间早期组显著更短(风险差-11.4天,95%CI -19.1至-3.7天);幸存者ICU停留时间和机械通气时间两组无显著差异。
- 不良事件:原文报告医院获得性肺炎为安全性指标,两组无显著差异,未报告其他不良事件。
证据类型、等级与局限
- 证据类型:回顾性行政数据库研究(倾向性评分匹配分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于机械通气且持续使用神经肌肉阻滞剂(罗库溴铵≥250 mg/d或维库溴铵≥50 mg/d连续至少2天)的ICU患者,早期(2天内)启动肠内营养可能与住院死亡率更低相关,且不增加医院获得性肺炎;作者认为该关联需进一步研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Whether enteral nutrition should be postponed in patients undergoing sustained treatment with neuromuscular blocking agents remains unclear. We evaluated the association between enteral nutrition initiated within 2 days of sustained neuromuscular blocking agent treatment and in-hospital mortality.
DESIGN: Retrospective administrative database study from July 2010 to March 2016.
SETTING: More than 1,200 acute care hospitals covering approximately 90% of all tertiary-care emergency hospitals in Japan.
PATIENTS: Mechanically ventilated patients, who had undergone sustained treatment with neuromuscular blocking agents in an ICU, were retrospectively reviewed. We defined patients who received sustained treatment with neuromuscular blocking agents as those who received either rocuronium at greater than or equal to 250 mg/d or vecuronium at greater than or equal to 50 mg/d for at least 2 consecutive days.
INTERVENTIONS: Enteral nutrition started within 2 days from the initiation of neuromuscular blocking agents (defined as early enteral nutrition).
MEASUREMENTS AND MAIN RESULTS: We identified 2,340 eligible patients during the 69-month study period. Of these, 378 patients (16%) had received early enteral nutrition. One-to-three propensity score matching created 374-1,122 pairs. The in-hospital mortality rate was significantly lower in the early than late enteral nutrition group (risk difference, -6.3%; 95% CI, -11.7% to -0.9%). There was no significant difference in the rate of hospital pneumonia between the two groups (risk difference, 2.8%; 95% CI, -2.7% to 8.3%). Length of hospital stay among survivors was significantly shorter in the early compared with the late enteral nutrition group (risk difference, -11.4 d; 95% CI, -19.1 to -3.7 d). There was no significant difference between the two groups in length of ICU stay or length of mechanical ventilation among survivors.
CONCLUSIONS: According to this retrospective database study, early enteral nutrition may be associated with lower in-hospital mortality with no increase in-hospital pneumonia in patients undergoing sustained treatment with neuromuscular blocking agents.
参考来源
- Ohbe H, Jo T, Matsui H, et al. Early Enteral Nutrition in Patients Undergoing Sustained Neuromuscular Blockade: A Propensity-Matched Analysis Using a Nationwide Inpatient Database. Crit Care Med. 2019. PMID: 31306255. doi:10.1097/CCM.0000000000003812
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。